- Home
- LU vs ANNX Comparison
LU vs ANNX Comparison
Compare LU & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | ANNX |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 726.1M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LU | ANNX |
|---|---|---|
| Price | $0.84 | $3.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $2.50 | ★ $15.43 |
| AVG Volume (30 Days) | 1.8M | ★ 3.4M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $2.54 |
| 52 Week High | $3.44 | $7.18 |
Technical Indicators
Market Signals| Indicator | LU | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 28.48 | 44.05 |
| Support Level | N/A | $3.71 |
| Resistance Level | $1.42 | $4.37 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 3.19 | 47.12 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.